Gefitinib

Also known as: ZD1839, Iressa, N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine, 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-, N-(3-Chlor-4-fluorphenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)chinazolin-4-amin

Gefitinib (CAS 184475-35-2) is a compound in the Organic Compounds category listed in the Jingsj chemical database. It has the molecular formula C22H24ClFN4O3 and a molecular weight of 446.902 g/mol. Key properties include a melting point of 119-1200C, a boiling point of 586.8±50.0 °C at 760 mmHg, a density of 1.3±0.1 g/cm3 and a flash point of 308.7±30.1 °C. It is classified under GHS with signal word Warning and hazard statements H302 — Harmful if swallowed, H315 — Causes skin irritation and H319 — Causes serious eye irritation. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 184475-35-2
Jingsj CID: J-47974-3
Molecular Formula: C₂₂H₂₄ClFN₄O₃
Molecular Weight: 446.902 g/mol
Category: Organic Compounds
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Melting Point	119-1200C
Boiling Point	586.8±50.0 °C at 760 mmHg
Density	1.3±0.1 g/cm3
Flash Point	308.7±30.1 °C
Exact Mass	446.152100
PSA	68.74000
LogP	4.11
Vapor Pressure	0.0±1.6 mmHg at 25°C
Refractive Index	1.621
Storage Conditions	Store at RT

GHS Safety & Compliance

IrritantSignal word: Warning

H302 — Harmful if swallowed
H315 — Causes skin irritation
H319 — Causes serious eye irritation
H335 — May cause respiratory irritation

Activity & Biological Data

Target	EGFR
Additional Information	[1]. Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005 Oct 17;93(8):915-23. [2]. Moasser MM, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001 Oct 1;61(19):7184-8. [3]. Morgillo F, et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3508-19. [4]. Miyake K, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats. J Med Invest. 2012;59(1-2):174-85. [5]. Noh CK, et al. Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats. J Sep Sci. 2017 Jul 27. [6]. Dhar D, et al. Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6.

Target

EGFR

Additional Information

[1]. Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005 Oct 17;93(8):915-23. [2]. Moasser MM, et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001 Oct 1;61(19):7184-8. [3]. Morgillo F, et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res. 2013 Jul 1;19(13):3508-19. [4]. Miyake K, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats. J Med Invest. 2012;59(1-2):174-85. [5]. Noh CK, et al. Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats. J Sep Sci. 2017 Jul 27. [6]. Dhar D, et al. Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6.

Customs & Trade Information

HS Code	2934999090
Summary	2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Frequently Asked Questions

What is the CAS number of Gefitinib?

The CAS number of Gefitinib is 184475-35-2.

What are the molecular formula and molecular weight of Gefitinib?

Gefitinib has molecular formula C22H24ClFN4O3 and molecular weight 446.902 g/mol.

Is Gefitinib hazardous?

Gefitinib has GHS signal word Warning and hazard statements H302 — Harmful if swallowed; H315 — Causes skin irritation; H319 — Causes serious eye irritation.

What are the upstream and downstream products of Gefitinib?

For Gefitinib, Upstream Products: 7-Methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4(3H)-one, 3-Chloro-4-fluoroaniline, 4-(3-Chloropropyl)morpholine; Downstream Products: O-Desmethyl gefitinib, 7-Methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4(3H)-one.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Gefitinib (CAS 184475-35-2)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-47974-3 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.